Last reviewed · How we verify
NCT05209568
Immune Responses to Gluten
NA trial testing Gluten Powder in Celiac Disease in 400 participants. Currently enrolling.
30 September 2028
Quick facts
| Lead sponsor | Boston Children's Hospital |
|---|---|
| Phase | NA |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | non randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | other |
| Enrollment | 400 |
| Start date | 15 January 2023 |
| Primary completion | 30 September 2028 |
| Estimated completion | 30 September 2029 |
| Sites | 2 locations across United States |
Drugs / interventions tested
- Gluten Powder
Conditions studied
- Celiac Disease — all drugs for Celiac Disease →
- Malabsorption Syndromes — all drugs for Malabsorption Syndromes →
- Digestive System Disease — all drugs for Digestive System Disease →
- Intestinal Disease — all drugs for Intestinal Disease →
Sponsor
Boston Children's Hospital
Who can join
Adults 2 to 101, any sex, with Celiac Disease or Malabsorption Syndromes. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a study of immune responses after eating gluten powder in people with celiac disease and healthy controls.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05209568
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Gluten Powder
Trials testing the same drug.
- NCT04614571 — T Cell Receptor (TCR) Sequencing and Transcriptional Profiling in Adult Celiac Disease Patients Undergoing Gluten Challe · NA · completed
Other recruiting trials for Celiac Disease
Currently open trials in the same condition.
- NCT07239336 — Study of DONQ52 in Active Celiac Disease · Phase 2 · recruiting
- NCT07585669 — Effects of Omega-3 Fatty Acids on Inflammation and Gut Microbiota in Celiac Disease · NA · recruiting
- NCT07063823 — A First-in-human Study to Evaluate the Safety and Tolerability of HB-2121 as a Diagnostic for Celiac Disease · Phase 1 · recruiting
- NCT06982963 — Randomized, Double Blind, Placebo-controlled Phase 2 Study in Adults With Celiac Disease · Phase 2 · recruiting
- NCT07177287 — The Effect of a Navigator Nurse- Supported Mobile Application Developed Based on the IMB Model on the Quality of Life of · NA · recruiting
Other Boston Children's Hospital trials
Trials by the same sponsor.
- NCT06804382 — Academic Detailing to Optimize PrEP Implementation in Pediatric Primary Care Settings: ADOPT-PrEP · NA · not yet recruiting
- NCT05113394 — Preventing Childhood Asthma Using Prophylactic House Dust Mite Allergen Immunotherapy · Phase 2 · withdrawn
- NCT06434220 — Effect of Predictive Model on ED Physician Assessments of Patient Disposition · NA · not yet recruiting
- NCT07476430 — Readiness Outcomes Affecting Return to Sport 3.0 · NA · not yet recruiting
- NCT06706336 — Radon Asthma Intervention Trial · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05209568 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Boston Children's Hospital
- Last refreshed: 23 April 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05209568.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing